Alimera’s Diabetic Macular Edema Drug Iluvien Gets Third FDA Rejection
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA cites concerns about safety and manufacturing in third “complete response” letter for intravitreal implant Iluvien in diabetic macular edema. Agency requests new trial and an advisory committee meeting in early 2014.